Type I diabetes (T1DM) is the second most common chronic illness effecting children in the
USA. Worldwide, Type I diabetes is increasing in incidence, and its underlying etiology
remains elusive. Nevertheless, recent data supports the notion that early and intensive
management of Type I diabetes can 1) decrease long-term complications of diabetes; and 2)
may significantly improve beta cell function and insulin secretion over ensuing years. To
this end, we propose using insulin pump therapy to preserve and/or enhance residual
endogenous B-cell secretory capacity among patients with newly diagnosed Type 1 DM.
Furthermore, we anticipate that early use of an insulin pump will improve glycemic control
beyond that achieved with standard multiple daily injection (MDI) therapy, and will be
well-tolerated by the patient. These data will provide important pilot information to
explore the potential role of intensive insulin pump therapy in the treatment of children
newly diagnosed with Type I diabetes. The specific aim of this study is to test the
following hypothesis: Early use of insulin pump therapy is effective in preserving or
enhancing residual endogenous pancreatic B-cell secretory capacity among patients with newly
diagnosed T1DM: Moreover, early use of an insulin pump will improve glycemic control beyond
that achieved with standard multiple injection therapy, and will be well-tolerated by the
- Medical history and clinical presentation consistent with the diagnosis of Type 1 DM.
- Age: 8-18 years
- Clinical presentation consistent with Type 2 DM.
- History of other chronic systemic inflammatory or autoimmune disease or other severe
- Concurrent pregnancy.
- Participation in other research protocols or use of other investigational agents
within 30 days of enrollment.